• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

The Top 5 Biosimilar Articles for the Week of July 7

July 11, 2025

Two More Pairs of Denosumab Biosimilars Enter US Market

July 09, 2025

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Featured Content

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 5th 2025

By Deana Ferreri, PhD

Article

Long-term data from the SAME study confirm that switching to infliximab biosimilars is safe and effective for patients with inflammatory bowel disease (IBD).

The Top 5 Biosimilar Articles for the Week of June 30

July 4th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 30, 2025.

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 3rd 2025

By Cameron Santoro

Article

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Real-World Data Suggest Long-Term Safety of CT-P13 in IBD, RA

July 2nd 2025

By Deana Ferreri, PhD

Article

The MEGA-J study reveals CT-P13's long-term safety and effectiveness in treating inflammatory bowel disease and rheumatoid arthritis, with minimal adverse reactions.

Biosimilars Rheumatology Roundup: June 2025

July 1st 2025

By Skylar Jeremias

Article

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and real-world efficacy insights.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

Article

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles

June 29th 2025

By Cameron Santoro

Video

Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.

The Top 5 Biosimilar Articles for the Week of June 23

June 27th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26th 2025

By Skylar Jeremias

Article

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25th 2025

By Skylar Jeremias

Article

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.